RET原癌基因在甲状腺癌中的研究进展  

Research Progress on RET Oncogene in Thyroid Carcinoma

作　　者：焦佳媛 邢久歌 柴宝山[1] JIAO Jiayuan;XING Jiuge;CHAI Baoshan(Pharmaceutical Research Laboratory,Shenyang Research Institute of Chemical Industry Co.,Ltd.,Shenyang 110021,China)

机构地区：[1]沈阳化工研究院有限公司医药研究室,沈阳110021

出　　处：《生物技术进展》2023年第6期895-899,共5页Current Biotechnology

基　　金：沈阳化工研究院资助项目(99000029)。

摘　　要：原癌基因RET(rearranged during transfection)在1985年被鉴定,随后,在甲状腺乳头状癌(papillary thyroid carcinoma,PTC)中发现了不同类型的RET/PTC染色体重排。在遗传性和散发性的甲状腺髓样癌(medullary thyroid carcinoma,MTC)中发现RET点突变基因。与PTC中RET的变化存在不同,MTC中RET的活化主要通过激活点突变。RET不同类型的重排活化与甲状腺癌的高发密切相关,RET不同的活化机制需对应不同的治疗对策。讨论了RET原癌基因在甲状腺乳头状癌和甲状腺髓样癌中的致病、诊断和预后的作用,以期为RET活化引起的甲状腺癌的治疗提供理论依据。Proto-oncogene rearranged during transfection(RET)was identified in 1985,and then,the different types of RET/PTC rearrangement of chromosomes were discovered in papillary thyroid carcinoma(PTC).Activating point mutations in the RET proto-oncogene were discovered in both hereditary and sporadic forms of medullary thyroid carcinoma(MTC).Different from the change of RET in PTC,the activation of RET in MTC is mainly through the activation point mutation.Thus,the different types of rearrangement activation of RET are closely related to the high incidence of thyroid cancer.Different activation mechanisms of RET will lead to different treatment strategies.In this review,we discussed the role of RET proto-oncogenes in the pathogenesis,diagnosis and prognosis of PTC and MTC,which was expected to provide reference for the thyroid carcinoma caused by RET activation.

关 键 词：原癌基因重排 甲状腺髓样癌 甲状腺乳头状癌 致病 诊断 预后 

分 类 号：Q279[生物学—细胞生物学] R73[医药卫生—肿瘤]